Seeing if DCog Short on an iPad can spot neurotoxicity in CAR-T patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study evaluates the use of the DCog Short, a self-reporting, tablet-based tool, to detect neurotoxicity in patients undergoing CAR-T cell therapy. It aims to determine how well the tool works in capturing neurotoxic symptoms and cognitive changes. Eligible participants are adults treated with CAR-T therapy who can use an iPad, with recruitment planned at Beth Israel Deaconess Medical Center. The FDA has not approved DCog Short for this purpose, and the study includes screening, questionnaires, and cognitive assessments to compare findings with standard monitoring. About 40 participants are expected to enroll in this single-site study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.
* Visual acuity of 20/100 or better.

Exclusion Criteria:

* patients \< 18 years old
* pregnant women
* prisoners
* adults unable to consent,
* participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad

Where it's running

• Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Jon Arnason, MD — Beth Israel Deaconess Medical Center
• Study coordinator: Jon Arnason, MD
• Email: jarnason@bidmc.harvard.edu
• Phone: (617) 667-9920

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Identifying biomarkers for CAR-T cell therapy in cancer patients

  This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.

  Recruiting University Hospital, Lille · Lille and 1 other locations · NCT07609485

• Remote rehabilitation for people receiving CAR-T cell therapy

  This project will test a home-based telerehabilitation program using interactive exercise, nutrition, behavioral support, and remote monitoring for people with lymphoma or myeloma who are getting CAR-T therapy.

  Recruiting University of Utah · Salt Lake City, Utah · NCT07390071

• CD19‑CAR T‑cell consolidation after TCRαβ/CD19‑depleted haploidentical family donor transplant for relapsed/refractory CD19+ B‑cell leukemia and lymphoma

  This will try giving CD19‑targeted CAR T cells shortly after a partially matched family‑donor transplant to children and young adults (≤21) with relapsed or refractory CD19+ B‑cell leukemia or lymphoma to see if the approach is safe and feasible.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07257419

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.